APPLICATION
ANDA202956
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-17
LATEST ACTION
2025-02-11
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription
Products
ZOLMITRIPTANPrescription
ZOLMITRIPTAN 5MG · TABLET, ORALLY DISINTEGRATING · ORAL
ZOLMITRIPTANPrescription
ZOLMITRIPTAN 2.5MG · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2025-02-11Labeling · Supplement 10 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.